Xiaotian T. Fang

Xiaotian T. Fang

Auto-generated profile, based on publicly available information

Xiaotian T. Fang

Yale School of Medicine New Haven CT USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JSJoshua Spurrier
Joshua Spurrier
LNLaShae Nicholson
LaShae Nicholson
XFXiaotian T. Fang
Xiaotian T. Fang
ASAustin J. Stoner
Austin J. Stoner
TTTakuya Toyonaga
Takuya Toyonaga
SSStephen M. Strittmatter
Stephen M. Strittmatter
Microglia-mediated synaptic loss contributes to the development of cognitive impairments in Alzheimer’s disease (AD). However, the basis for this immune-mediated attack on synapses remains to be elucidated. Treatment with the metabotropic glutamate receptor 5 (mGluR5) silent allosteric modulator (SAM), BMS-984923, prevents β-amyloid oligomer–induced aberrant synaptic signaling while preserving physiological glutamate response. Here, we show that oral BMS-984923 effectively occupies brain mGluR5 sites visualized by [ 18 F]FPEB positron emission tomography (PET) at doses shown to be safe in rodents and nonhuman primates. In aged mouse models of AD ( APPswe/PS1 Δ E9 overexpressing transgenic and App NL-G-F / hMapt double knock-in), SAM treatment fully restored synaptic density as measured by [ 18 F]SynVesT-1 PET for SV2A and by histology, and the therapeutic benefit persisted after drug washout. Phospho-TAU accumulation in double knock-in mice was also reduced by SAM treatment. Single-nuclei transcriptomics demonstrated that SAM treatment in both models normalized expression patterns to a far greater extent in neurons than glia. Last, treatment prevented synaptic localization of the complement component C1Q and synaptic engulfment in AD mice. Thus, selective modulation of mGluR5 reversed neuronal gene expression changes to protect synapses from damage by microglial mediators in rodents.

25 November 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
SSStina Syvanen
Stina Syvanen
XFXiaotian T Fang
Xiaotian T Fang
RFRebecca Faresjö
Rebecca Faresjö
JRJohanna Rokka
Johanna Rokka
LLLars Lannfelt
Lars Lannfelt
DSDag Sehlin
Dag Sehlin
Antibodies are attractive as radioligands due to their outstanding specificity and high affinity, but their inability to cross the blood–brain barrier (BBB) limits their use for CNS targets. To enhance brain distribution, amyloid-β (Aβ) antibodies were fused to a transferrin receptor (TfR) antibody fragment, enabling receptor mediated transport across the BBB. The aim of this study was to label these bispecific antibodies with fluorine-18 and use them for Aβ PET imaging. Bispecific antibody ligands RmAb158-scFv8D3 and Tribody A2, both targeting Aβ and TfR, were functionalized with trans-cyclooctene (TCO) groups and conjugated with 18F-labeled tetrazines through an inverse electron demand Diels–Alder reaction performed at ambient temperature. 18F-labeling did not affect antibody binding in vitro, and initial brain uptake was high. Conjugates with the first tetrazine variant ([18F]T1) displayed high uptake in bone, indicating extensive defluorination, a problem that was resolved with the second and third tetrazine variants ([18F]T2 and [18F]T3). Although the antibody ligands’ half-life in blood was too long to optimally match the physical half-life of fluorine-18 (t1/2 = 110 min), [18F]T3-Tribody A2 PET seemed to discriminate transgenic mice (tg-ArcSwe) with Aβ deposits from wild-type mice 12 h after injection. This study demonstrates that 18F-labeling of bispecific, brain penetrating antibodies is feasible and, with further optimization, could be used for CNS PET imaging.

15 May 2021 in NeuroImage
Verified
Journal Article
Open access
XFXiaotian T. Fang
Xiaotian T. Fang
TTTakuya Toyonaga
Takuya Toyonaga
AHAnsel T. Hillmer
Ansel T. Hillmer
DMDavid Matuskey
David Matuskey
SHSophie E. Holmes
Sophie E. Holmes
RCRichard E. Carson
Richard E. Carson
The human brain is inherently organized into distinct networks, as reported widely by resting-state functional magnetic resonance imaging (rs-fMRI), which are based on blood-oxygen-level-dependent (BOLD) signal fluctuations. 11C-UCB-J PET maps synaptic density via synaptic vesicle protein 2A, which is a more direct structural measure underlying brain networks than BOLD rs-fMRI. The aim of this study was to identify maximally independent brain source networks, i.e., "spatial patterns with common covariance across subjects", in 11C-UCB-J data using independent component analysis (ICA), a data-driven analysis method. Using a population of 80 healthy controls, we applied ICA to two 40-sample subsets and compared source network replication across samples. We examined the identified source networks at multiple model orders, as the ideal number of maximally independent components (IC) is unknown. In addition, we investigated the relationship between the strength of the loading weights for each source network and age and sex. Thirteen source networks replicated across both samples. We determined that a model order of 18 components provided stable, replicable components, whereas estimations above 18 were not stable. Effects of sex were found in two ICs. Nine ICs showed age-related change, with 4 remaining significant after correction for multiple comparison. This study provides the first evidence that human brain synaptic density can be characterized into organized covariance patterns. Furthermore, we demonstrated that multiple synaptic density source networks are associated with age, which supports the potential utility of ICA to identify biologically relevant synaptic density source networks.

1 February 2017 in Neuropharmacology
Verified
Journal Article
Open access
XFXiaotian T. Fang
Xiaotian T. Fang
JEJonas Eriksson
Jonas Eriksson
GAGunnar Antoni
Gunnar Antoni
UYUlrika Yngve
Ulrika Yngve
LCLinda Cato
Linda Cato
SSStina Syvanen
Stina Syvanen
Alzheimer's disease (AD) is characterized by aggregation of amyloid beta (Aβ) into insoluble plaques. Intermediates, Aβ oligomers (Aβo), appear to be the mechanistic cause of disease. The de facto PET AD ligand, [11C]PIB, binds and visualizes Aβ plaque load, which does not correlate well with disease severity. Therefore, finding a dynamic target that changes with pathology progression in AD is of great interest. Aβo alter synaptic plasticity, inhibit long-term potentiation, and facilitate long-term depression; key mechanisms involved in memory and learning. In order to convey these neurotoxic effects, Aβo requires interaction with the metabotropic glutamate 5 receptor (mGluR5). The aim was to investigate in vivo mGluR5 changes in an Aβ pathology model using PET. Wild type C57/BL6 (wt) and AβPP transgenic mice (tg-ArcSwe), 4, 8, and 16 months old, were PET scanned with [11C]ABP688, which is highly specific to mGluR5, to investigate changes in mGluR5. Mouse brains were extracted postscan and mGluR5 and Aβ protofibril levels were assessed with immunoblotting and ELISA respectively. Receptor-dense brain regions (hippocampus, thalamus, and striatum) displayed higher [11C]ABP688 concentrations corresponding to mGluR5 expression pattern. Mice had similar uptake levels of [11C]ABP688 regardless of genotype or age. Immunoblotting revealed general decline in mGluR5 expression and elevated levels of mGluR5 in 16 months old tg-ArcSwe compared with wt mice. [11C]ABP688 could visualize mGluR5 in the mouse brain. In conclusion, mGluR5 levels were found to decrease with age and tended to be higher in tg-ArcSwe compared with wt mice, however these changes could not be quantified with PET.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
XFXiaotian T. Fang
Xiaotian T. Fang
GWGraham Williams
Graham Williams
SCStacy Castner
Stacy Castner
DHDaniel Holden
Daniel Holden
MZMing‐Qiang Zheng
Ming‐Qiang Zheng
RCRichard Carson
Richard Carson
Background: Nonhuman primates (NHPs) exhibit age‐related cognitive impairments, synaptic loss, and accumulation of tau and amyloid in dorsolateral prefrontal cortex (dlPFC) and entorhinal cortex (ERC). In a cohort of NHPs with longitudinal cognitive data, we perform SV2A ([11C]UCB‐J), amyloid ([11C]PIB), and tau ([18F]MK‐6240) PET. We aim to 1) investigate in vivo relationships and age‐related change in amyloid, tau, and synaptic density (SV2A) and 2) to relate these to cognition in NHPs.Method: Middle‐aged (n = 5, 10.4 ± 0.5 y.o.) and old (n = 17, 19.9 ± 2.7 y.o.) NHPs were dynamically PET scanned (FOCUS 220) following i.v. injection of each of [18F]MK‐6240 (173 ± 12 MBq), [ 11C]PIB (131 ± 52 MBq), and [11C]UCB‐J (105 ± 34 MBq). Structural MR scans were acquired for registering PET to template space. Outcome measures were SUVR40‐60 for [11C]PIB, SRTM2‐derived DVR for [11C]UCB‐J, and SUVR90‐110 for [18F]MK‐6240. Cerebellum was used as reference ([11C]PIB, [11C]UCB‐J), and cerebellar gray matter for [18F]MK‐6240. A subset of the old NHPs (n = 15) were tested with the spatial‐delayed response task to assess working memory performance. Outcome measures: number‐of‐wells, time‐delay, and combined score (number‐of‐wells × time‐delay); higher score indicates better memory performance.Result: No regional mean differences were observed in amyloid or SV2A between middle‐aged and old NHPs, though old NHPs exhibited higher variance for all tracers; mean tau was elevated in dlPFC (p = 0.0031) and hippocampus (HC, p = 0.011) in old NHP compared with middle‐aged (Figure 1). In ERC, a positive relationship was found between tau and amyloid), and in HC, a negative correlation was found between tau and SV2A (Figure 2A). Synaptic density displayed a positive relationship with combined score both in dlPFC (p = 0.0055, R2 = 0.46) and HC (p = 0.029, R2 = 0.32) (Figure 2B). Tau had a negative relationship with number‐of‐wells in dlPFC (p = 0.05, R2 = 0.40), and combined score in HC (p = 0.015, R2 = 0.40).Conclusion: NHPs exhibit age‐related changes in canonical AD biomarkers as seen by PET. PET markers of SV2A, tau, and amyloid in known early‐pathology regions (dlPFC, HC) correlate appropriately with working memory performance. These studies demonstrate the potential of NHPs as a highly useful model for human AD.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
XFXiaotian T. Fang
Xiaotian T. Fang
AMAdam P. Mecca
Adam P. Mecca
MNMika Naganawa
Mika Naganawa
RORyan S. O'DEll
Ryan S. O'DEll
MCMing‐Kai Chen
Ming‐Kai Chen
RCRichard E. Carson
Richard E. Carson